BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Björck F, Kadhim H, Själander A. Predictors for INR-control in a well-managed warfarin treatment setting.J Thromb Thrombolysis. 2019;47:227-232. [PMID: 30411185 DOI: 10.1007/s11239-018-1765-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang N, Qiu S, Yang Y, Zhang C, Gu ZC, Qian Y. Physician-Pharmacist Collaborative Clinic Model to Improve Anticoagulation Quality in Atrial Fibrillation Patients Receiving Warfarin: An Analysis of Time in Therapeutic Range and a Nomogram Development. Front Pharmacol 2021;12:673302. [PMID: 34177585 DOI: 10.3389/fphar.2021.673302] [Reference Citation Analysis]
2 Rydberg DM, Linder M, Malmström RE, Andersen M. Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication. Eur J Clin Pharmacol 2020;76:867-76. [PMID: 32222786 DOI: 10.1007/s00228-020-02856-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
3 Dalmau Llorca MR, Aguilar Martín C, Carrasco-Querol N, Hernández Rojas Z, Forcadell Drago E, Rodríguez Cumplido D, Castro Blanco E, Gonçalves AQ, Fernández-Sáez J. Anticoagulation Control with Acenocoumarol or Warfarin in Non-Valvular Atrial Fibrillation in Primary Care (Fantas-TIC Study). Int J Environ Res Public Health 2021;18:5700. [PMID: 34073370 DOI: 10.3390/ijerph18115700] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Toorop MMA, Chen Q, Kruip MJHA, van der Meer FJM, Nierman MC, Faber L, Goede L, Cannegieter SC, Lijfering WM. Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence? J Thromb Haemost 2021. [PMID: 34779140 DOI: 10.1111/jth.15592] [Reference Citation Analysis]
5 Beyene K, Chan AHY, Näslund P, Harrison J. Patient-related factors associated with oral anticoagulation control: a population-based cohort study. Int J Pharm Pract 2021:riab041. [PMID: 34302345 DOI: 10.1093/ijpp/riab041] [Reference Citation Analysis]
6 Okumura K, Yamashita T, Akao M, Atarashi H, Ikeda T, Koretsune Y, Shimizu W, Tsutsui H, Toyoda K, Hirayama A, Yasaka M, Yamaguchi T, Teramukai S, Kimura T, Kaburagi J, Takita A, Inoue H. Characteristics and anticoagulant treatment status of elderly non-valvular atrial fibrillation patients with a history of catheter ablation in Japan: Subanalysis of the ANAFIE registry. J Cardiol 2020;76:446-52. [PMID: 32624299 DOI: 10.1016/j.jjcc.2020.06.015] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM, Cronshaw R. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol 2021; 13(9): 483-492 [PMID: 34621493 DOI: 10.4330/wjc.v13.i9.483] [Reference Citation Analysis]